insights_auto
Outlook: 65.5% bullish·1.8% bearish
Go to analysischevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$742.12
arrow_upward
+0.46%(+3.40) 1D
$742.12
0.00% (0.00)
todayPre-market
Closed: Oct 7, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$738.05
High
$753.68
Low
$734.18
Mkt. cap
76.40B
Avg. vol.
719.48K
Volume
314.00
Dividend
0.51%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.35
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$738.05
High
$753.68
Low
$734.18
Mkt. cap
76.40B
Avg. vol.
719.48K
Volume
314.00
Dividend
0.51%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.35
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
Investing.com
·
2 hours ago
Raymond James reiterates Regeneron stock rating on Eylea trends
Yahoo Finance
·
6 hours ago
Is Biohaven (BHVN) Quietly Recasting Its Oncology Strategy Through Deeper Ties With Regeneron?
AD HOC NEWS
·
6 hours ago
Regeneron announces 10 ESMO abstracts; stock pre-market at EUR 661.25, minus 0.24 percent
GuruFocus
·
18 hours ago
REGN Maintains Buy Rating -- Price Target Raised to $780 by Trui
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com